Greg Smith, the former Goldman Sachs vice president who resigned with guns ablazin in a March New York Times op-ed blasting Goldman, was interviewed on CBS’s 60 Minutes Sunday night. Here’s the full video:
Reactions on Twitter from finance journos and investors were mostly critical of Smith. The consensus: at best he was terribly naive, and at worst he’s feigning surprise to cash in on his departure:
High beta stocks are the Sofia Vergaras of the investing world: Sexy! But as much as you may like it to be true, they’re probably not your best friend.
In June, the American Society of Clinical Oncology (ASCO) hosted its 60th Annual Meeting, drawing over 40,000 attendees from around the globe. This year’s event largely focused on validating revolutionary treatment categories like Chimeric antigen receptor (CAR) T-cell therapies and antibody drug conjugates (ADCs). Given proven clinical benefits across a wider array of cancer types, we expect these novel treatment categories to become increasingly important in the fight against cancer and the growth profiles of select companies in the healthcare space.
Emerging markets, energy and commodities may be worth a look
Make sure you understand how an ETF works before you buy it.
